Implementation of a CKD checklist for primary care providers

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 9, 2014, Pages 1526-1535

  Mendu, Mallika L ^a   Schneider, Louise I ^a   Aizer, Ayal A ^b   Singh, Karandeep ^a   Leaf, David E ^a   Lee, Thomas H ^a,c   Waikar, Sushrut S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Division of General Medicine Brigham and Women’s Hospital Harvard Medical School ^*  (United States)

^c Press Ganey Associates Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; NONSTEROID ANTIINFLAMMATORY AGENT; PARATHYROID HORMONE; PHOSPHATE;

ABSENCE OF SIDE EFFECTS; AGED; ALBUMINURIA; ARTICLE; CHECKLIST; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DECISION MAKING; ELECTRONIC MEDICAL RECORD; FEMALE; GENERAL PRACTITIONER; HEALTH PROGRAM; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; PATIENT CARE; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PROTEINURIA; TREATMENT OUTCOME; VACCINATION; PRIMARY HEALTH CARE; PROTOCOL COMPLIANCE; RENAL INSUFFICIENCY, CHRONIC; STATISTICS AND NUMERICAL DATA;

AGED; CHECKLIST; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84923762582     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01660214     Document Type: Article

References (50)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038–2047, 2007.
2. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39[Suppl 1]: S1–S266, 2002.
3. United States Renal Data System: USRDS 2010 Annual Data Report. Bethesda, MD, National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Disease, 2010. Available at: http://www.usrds.org/2010/pdf/v1_00a_intros.PDF. Accessed December 1, 2013.
4. Pereira BJ: Optimization of pre-ESRD care: The key to improved dialysis outcomes. Kidney Int 57: 351–365, 2000.
5. Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members: Evaluation and management of chronic kidney disease: synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158:825–830, 2013.
6. Eknoyan G: Meeting the challenges of the new K/DOQI guidelines. Am J Kidney Dis 41[Suppl]: 3–10, 2003.
7. Charles RF, Powe NR, Jaar BG, Troll MU, Parekh RS, Boulware LE: Clinical testing patterns and cost implications of variation in the evaluation of CKD among US physicians. Am J Kidney Dis 54:227–237, 2009.
8. Morrow BD, Stewart IJ, Barnes EW, Cotant CL: Chronic kidney disease management in an academic internal medicine clinic. Clin Exp Nephrol 14: 137–143, 2010.
9. Allen AS, Forman JP, Orav EJ, Bates DW, Denker BM, Sequist TD: Primary care management of chronic kidney disease. J Gen Intern Med 26: 386–392, 2011.
10. Philipneri MD, Rocca Rey LA, Schnitzler MA, Abbott KC, Brennan DC, Takemoto SK, Buchanan PM, Burroughs TE, Willoughby LM, Lentine KL: Delivery patterns of recommended chronic kidney disease care in clinical practice: Administrative claims-based analysis and systematic literature review. Clin Exp Nephrol 12: 41–52, 2008.
11. Gawande A: The checklist: If something so simple can transform intensive care, what else can it do? New Yorker : 86–101, 2007.
12. Haynes AB, Weiser TG, Berry WR, Lipsitz SR, Breizat AH, Dellinger EP, Herbosa T, Joseph S, Kibatala PL, Lapitan MC, Merry AF, Moorthy K, Reznick RK, Taylor B, Gawande AA; Safe Surgery Saves Lives Study Group: A surgical safety checklist to reduce morbidity and mortality in a global population. N Engl J Med 360: 491–499, 2009.
13. Weiss CH, Persell SD, Wunderink RG, Baker DW: Empiric antibiotic, mechanical ventilation, and central venous catheter duration as potential factors mediating the effect of a checklist prompting intervention on mortality: An exploratory analysis. BMC Health Serv Res 12: 198, 2012.
14. Teixeira PG, Inaba K, Dubose J, Melo N, Bass M, Belzberg H, Demetriades D: Measurable outcomes of quality improvement using a daily quality rounds checklist: two-year prospective analysis of sustainability in a surgical intensive care unit. J Trauma Acute Care Surg 75: 717–721, 2013.
15. Saweirs WW, Goddard J: What are the best treatments for early chronic kidney disease? A background paper prepared for the UK Consensus Conference on early chronic kidney disease. Nephrol Dial Transplant 22[Suppl 9]: ix31–ix38, 2007.
16. Vesco KK, Whitlock EP, Eder M, Lin J, Burda BU, Senger CA, Holmes RS, Fu R, Zuber S. Screening for Cervical Cancer: A Systematic Evidence Reviewfor theU.S. Preventive Services Task Force Agency for Healthcare Research and Quality (US); 2011 May. Report No.: 11-05156-EF-1.
17. Humphrey LL, Helfand M, Chan BK, Woolf SH: Breast cancer screening: A ummary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137: 347–360, 2002.
18. Advisory Committee on Immunization Practices: Recommended adult immunization schedule: United States, 2013. Ann Intern Med 158: 191–199, 2013.
19. Fleming C, Whitlock EP, Beil TL, Lederle FA: Screening for abdominal aortic aneurysm: A best-evidence systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 142:203–211, 2005.
20. Holden DJ, Jonas DE, Porterfield DS, Reuland D, Harris R: Systematic review: Enhancing the use and quality of colorectal cancer screening. Ann Intern Med 152: 668–676, 2010.
21. Jung SY, Rosenzweig M, Linkov F, Brufsky A, Weissfeld JL, Sereika SM: Comorbidity as a mediator of survival disparity between younger and older women diagnosed with metastatic breast cancer. Hypertension 59: 205–211, 2012.
22. Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP: The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 61: 1234–1240, 2008.
23. Ingelfinger JR: Through the looking glass: anemia guidelines, vested interests, and distortions. Clin J Am Soc Nephrol 2: 415–417, 2007.
24. Kovesdy CP, Mehrotra R, Kalantar-Zadeh K: Battleground:Chronic kidney disorders mineral and bone disease—calcium obsession, vitamin D, and binder confusion. Clin J Am Soc Nephrol 3: 168–173, 2008.
25. Maki DD, Ma JZ, Louis TA, Kasiske BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 155: 1073–1080, 1995.
26. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL: Blood pressure control, proteinuria, and the progression of renal disease. The Modification ofDiet in Renal Disease Study. Ann Intern Med 123:754–762, 1995.
27. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560–2572, 2003.
28. Peralta CA, Norris KC, Li S, Chang TI, Tamura MK, Jolly SE, Bakris G, McCullough PA, Shlipak M; KEEP Investigators: Blood pressure components and end-stage renal disease in persons with chronic kidney disease: The Kidney Early Evaluation Program (KEEP). Arch Intern Med 172: 41–47, 2012.
29. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 65:2309–2320, 2004.
30. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL: The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: Results of the African American study of kidney disease and hypertension. Arch Intern Med 165: 947–953, 2005.
31. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD: Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 48: 8–20, 2006.
32. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A metaanalysis of patient-level data. Ann Intern Med 135: 73–87, 2001.
33. UK Prospective Diabetes Study (UKPDS)Group: Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853, 1998.
34. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28: 103–117, 1995.
35. Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL: Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 14: 479–487, 2003.
36. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellströöm B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomized placebo-controlled trial. Lancet 377: 2181–2192, 2011.
37. Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, Frank C, Klarenbach S, Hemmelgarn BR: NSAID use and progression of chronic kidney disease. Am J Med 120: e1–e7, 2007.
38. Kausz A, Pahari D: The value of vaccination in chronic kidney disease. Semin Dial 17: 9–11, 2004.
39. Navaneethan SD, Kandula P, Jeevanantham V, Nally JV Jr, Liebman SE: Referral patterns of primary care physicians for chronic kidney disease in general population and geriatric patients. Clin Nephrol 73: 260–267, 2010.
40. Greer RC, Powe NR, Jaar BG, Troll MU, Boulware LE: Effect of primary care physicians’ use of estimated glomerular filtration rate on the timing of their subspecialty referral decisions. BMC Nephrol 12: 1, 2011.
41. Boulware LE, Troll MU, Jaar BG, Myers DI, Powe NR: Identification and referral of patients with progressive CKD: A national study. Am J Kidney Dis 48: 192–204, 2006.
42. Rutkowski M, Mann W, Derose S, Selevan D, Pascual N, Diesto J, Crooks P: Implementing KDOQI CKD definition and staging guidelines in Southern California Kaiser Permanente. Am J Kidney Dis 53[Suppl 3]: S86–S99, 2009.
43. Fox CH, Swanson A, Kahn LS, Glaser K, Murray BM: Improving chronic kidney disease care in primary care practices: An upstate New York practice-based research network (UNYNET) study. J Am Board Fam Med 21: 522–530, 2008.
44. U.S. Department of Veterans Affairs: VA clinical practice guideline for management of chronic kidney disease in primary care. 2008. Accessed at: http://www.healthquality.va.gov/guidelines/CD/ckd/ckd_v478.pdf. Date Accessed December 1,2013.
45. Manley HJ: Disease progression and the application of evidencebased treatment guidelines diagnose it early: A case for screening and appropriate management. JManag Care Pharm13 [Suppl D]: S6–S12, 2007.
46. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR: Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 282: 1458–1465, 1999.
47. Oliveras A, Schmieder RE: Clinical situations associated with difficult-to-control hypertension. J Hypertens 31[Suppl 1]: S3–S8, 2013.
48. Gallagher H, de Lusignan S, Harris K, Cates C: Qualityimprovement strategies for the management of hypertension in chronic kidney disease in primary care: a systematic review. Br J Gen Pract 60: e258–e265, 2010.
49. McCambridge J, Witton J, Elbourne DR: Systematic review of the Hawthorne effect: New concepts are needed to study research participation effects. J Clin Epidemiol Nov: 22, 2013.
50. Garrouste-Orgeas M, Soufir L, Tabah A, Schwebel C, Vesin A, Adrie C, Thuong M, Timsit JF; Outcomerea Study Group: A multifaceted program for improving quality of care in intensive care units: IATROREF study. Crit Care Med 40: 468–476, 2012.